September 20th 2024
The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Key to New Treatments: Discovering What Turns a Hedgehog Off
October 14th 2015Researchers note that chronic Hedgehog (Hh) pathway stimulation has been shown in prostate, lung, and ovarian cancers, and that zinc levels decrease early in prostate cancer continuing to castration-resistant disease. Researchers are exploring whether or not zinc may suppress the autocatalysis in the Hh precursor and inhibit production of biologically active Hh ligand.
Read More
Anamorelin Shows Increased Survival in Non-Small Cell Lung Cancer
October 9th 2015Researchers discovered that the use of anamorelin among patients with advanced non-small cell lung cancer considerably helped more patients stabilize or gain lean body mass, a factor that consequently enables patients with cachexia to survive longer.
Read More
Dr. Pelosof on Therapies for Never Smokers With NSCLC
October 2nd 2015Lorraine Pelosof, MD, PhD, assistant professor, Division of Hematology/Oncology, The University of Texas Southwestern Medical Center, discusses targets and possible therapies for never smokers diagnosed with non-small cell lung cancer (NSCLC).
Read More
FDA Decision Nears for Pembrolizumab in Lung Cancer
October 2nd 2015Data from the pivotal KEYNOTE-001 trial showing pembrolizumab's efficacy in pretreated non-small cell lung cancer were presented just days before the FDA is scheduled to make its approval decision on the PD-1 inhibitor in this setting (October 2, 2015).
Read More
EGFR-Positive Squamous NSCLC Survival Improved by Cetuximab
September 15th 2015When cetuximab (Erbitux) was added to chemotherapy, the risk of death was reduced by 44% for patients with advanced squamous non-small cell lung cancer (NSCLC) whose tumors test positive for EGFR gene amplification.
Read More
High Response Rate Produced by Osimertinib in EGFR T790M-Mutant NSCLC
September 15th 2015Osimertinib (AZD9291), the third-generation TKI, demonstrated a 71% objective response rate (ORR) in those with EGFR T790M-mutant non-small cell lung cancer (NSCLC), following resistance to frontline anti-EGFR therapy.
Read More
Bevacizumab With Chemotherapy Doublet Improves Survival for Patients With Mesothelioma
September 11th 2015By adding bevacizumab (Avastin) to a standard chemotherapy doublet, the risk of death is reduced by 24%, with the risk of disease reducing by 39%, in patients who have malignant pleural mesothelioma (MPM).
Read More
Alectinib Granted Priority Review by the FDA in NSCLC
September 9th 2015The FDA recently granted alectinib a priority review designation for patients who have ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) and progressed or are intolerant to crizotinib (Xalkori).
Read More